Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have received an average recommendation of "Buy" from the nine research firms that are covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $22.14.
Several analysts recently issued reports on the company. HC Wainwright reissued a "buy" rating and issued a $21.00 price target on shares of Lexeo Therapeutics in a report on Thursday. Chardan Capital reissued a "buy" rating and issued a $23.00 price target on shares of Lexeo Therapeutics in a report on Friday, October 25th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $24.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, August 13th.
Read Our Latest Research Report on LXEO
Shares of LXEO opened at $7.93 on Friday. The company has a market capitalization of $262.17 million and a P/E ratio of -0.54. Lexeo Therapeutics has a one year low of $7.54 and a one year high of $22.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.38 and a current ratio of 9.38. The stock has a 50-day moving average price of $9.71 and a 200 day moving average price of $12.54.
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.64) EPS for the quarter, hitting analysts' consensus estimates of ($0.64). Sell-side analysts forecast that Lexeo Therapeutics will post -2.76 EPS for the current fiscal year.
In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 5,000 shares of the business's stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $10.65, for a total value of $53,250.00. Following the transaction, the chief executive officer now owns 120,695 shares in the company, valued at $1,285,401.75. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 15,000 shares of company stock valued at $151,400. Insiders own 4.50% of the company's stock.
Several large investors have recently made changes to their positions in the business. Janus Henderson Group PLC raised its holdings in Lexeo Therapeutics by 9.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company's stock valued at $39,802,000 after acquiring an additional 210,047 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in Lexeo Therapeutics in the 1st quarter valued at approximately $75,000. American International Group Inc. acquired a new position in Lexeo Therapeutics in the 1st quarter valued at approximately $79,000. Vanguard Group Inc. raised its holdings in Lexeo Therapeutics by 15.8% in the 1st quarter. Vanguard Group Inc. now owns 481,755 shares of the company's stock valued at $7,554,000 after acquiring an additional 65,573 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Lexeo Therapeutics by 12.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company's stock valued at $510,000 after acquiring an additional 3,483 shares in the last quarter. Institutional investors and hedge funds own 60.67% of the company's stock.
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Lexeo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.
While Lexeo Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.